Antispasmodics
Antispasmodics are effective in reducing abdominal pain associated with visceral organs, bloating, and bowel habit changes and are commonly used as “on-demand therapy.” A relatively regular intake of antispasmodics may help patients with functional gastrointestinal disease exacerbation. Irritable bo...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Korean College of Helicobacter and Upper Gastrointestinal Research
2022-06-01
|
| Series: | The Korean Journal of Helicobacter and Upper Gastrointestinal Research |
| Subjects: | |
| Online Access: | http://www.helicojournal.org/upload/pdf/kjhugr-2022-0012.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849709742305312768 |
|---|---|
| author | Kyung Ho Song |
| author_facet | Kyung Ho Song |
| author_sort | Kyung Ho Song |
| collection | DOAJ |
| description | Antispasmodics are effective in reducing abdominal pain associated with visceral organs, bloating, and bowel habit changes and are commonly used as “on-demand therapy.” A relatively regular intake of antispasmodics may help patients with functional gastrointestinal disease exacerbation. Irritable bowel syndrome and functional dyspepsia are representative functional gastrointestinal diseases with abdominal pain and bloating as the main symptoms. Most of the clinical data on antispasmodics are obtained from studies on functional gastrointestinal diseases including irritable bowel syndrome. Antispasmodics can be safely used for prolonged periods without serious adverse effects; however, different antispasmodics have different anticholinergic potencies. Antispasmodics with strong anticholinergic effects should be prescribed with caution to patients with glaucoma or prostatic hypertrophy-induced dysuria and to those driving vehicles, operating machinery, or receiving other anticholinergic drugs in combination. Antispasmodics meeting US Food and Drug Administration guidelines for efficacy, those showing relatively consistent efficacy in different trials, and those with prokinetic effects are currently available. Many patients with upper gastrointestinal symptoms have overlapping functional gastrointestinal disorders and may require antispasmodic drugs. Alternatively, tricyclic antidepressant or ramosetron use can be considered in patients with irritable bowel syndrome. This review summarizes the clinical data and characteristics of antispasmodics, particularly those available in South Korea. |
| format | Article |
| id | doaj-art-1a708d9934af4e3d98b849f4c6f37d3f |
| institution | DOAJ |
| issn | 1738-3331 |
| language | English |
| publishDate | 2022-06-01 |
| publisher | Korean College of Helicobacter and Upper Gastrointestinal Research |
| record_format | Article |
| series | The Korean Journal of Helicobacter and Upper Gastrointestinal Research |
| spelling | doaj-art-1a708d9934af4e3d98b849f4c6f37d3f2025-08-20T03:15:10ZengKorean College of Helicobacter and Upper Gastrointestinal ResearchThe Korean Journal of Helicobacter and Upper Gastrointestinal Research1738-33312022-06-0122210210710.7704/kjhugr.2022.0012729AntispasmodicsKyung Ho SongAntispasmodics are effective in reducing abdominal pain associated with visceral organs, bloating, and bowel habit changes and are commonly used as “on-demand therapy.” A relatively regular intake of antispasmodics may help patients with functional gastrointestinal disease exacerbation. Irritable bowel syndrome and functional dyspepsia are representative functional gastrointestinal diseases with abdominal pain and bloating as the main symptoms. Most of the clinical data on antispasmodics are obtained from studies on functional gastrointestinal diseases including irritable bowel syndrome. Antispasmodics can be safely used for prolonged periods without serious adverse effects; however, different antispasmodics have different anticholinergic potencies. Antispasmodics with strong anticholinergic effects should be prescribed with caution to patients with glaucoma or prostatic hypertrophy-induced dysuria and to those driving vehicles, operating machinery, or receiving other anticholinergic drugs in combination. Antispasmodics meeting US Food and Drug Administration guidelines for efficacy, those showing relatively consistent efficacy in different trials, and those with prokinetic effects are currently available. Many patients with upper gastrointestinal symptoms have overlapping functional gastrointestinal disorders and may require antispasmodic drugs. Alternatively, tricyclic antidepressant or ramosetron use can be considered in patients with irritable bowel syndrome. This review summarizes the clinical data and characteristics of antispasmodics, particularly those available in South Korea.http://www.helicojournal.org/upload/pdf/kjhugr-2022-0012.pdfparasympatholyticsirritable bowel syndromedrug-related side effects and adverse reactionscholinergic antagonistsabdominal pain |
| spellingShingle | Kyung Ho Song Antispasmodics The Korean Journal of Helicobacter and Upper Gastrointestinal Research parasympatholytics irritable bowel syndrome drug-related side effects and adverse reactions cholinergic antagonists abdominal pain |
| title | Antispasmodics |
| title_full | Antispasmodics |
| title_fullStr | Antispasmodics |
| title_full_unstemmed | Antispasmodics |
| title_short | Antispasmodics |
| title_sort | antispasmodics |
| topic | parasympatholytics irritable bowel syndrome drug-related side effects and adverse reactions cholinergic antagonists abdominal pain |
| url | http://www.helicojournal.org/upload/pdf/kjhugr-2022-0012.pdf |
| work_keys_str_mv | AT kyunghosong antispasmodics |